Simultaneous PD-1/VEGF/CTLA-4 blockade aims to compress multi-drug regimens into a single infusion, raising questions about ...

Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ...

Initial results from the dose escalation part of the first-in-human phase 1/2 trial of DS-3939 demonstrated promising ...

Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced the latest results from the ongoing Phase I/II CLINCH ...

Incyte (INCY) announced the first clinical data evaluating its TGFbetaR2PD-1 bispecific antibody for patients with microsatellite stable, MSS, ...

BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesionsData support further development of BT-001 in solid tumors ...

Nurix Therapeutics (NRIX) announced the presentation of new clinical data from its first-in-human Phase 1a study of NX-1607, a first-in-class oral ...

They may cause temporary side effects: Some studies have found that using exosomes can cause temporary symptoms such as ...

Learn how accelerating drug discovery is reshaping the pathway from lab findings to effective therapies with real-world data.

In the phase 1 portion of the trial, two doses of gedatolisib were administered IV on an intermittent schedule (Days 1, 8, 15 ...

GSK may be happy with the latest readouts from two Hansoh-partnered antibody-drug conjugates, but the Big Pharma’s oncology R ...